Alimera Sciences Inc.
Alimera Sciences Inc. is listed today as Alimera Sciences: market value, financials and filings are on its company page.
Acquired
Matched to this startup by its exact name; the buyer's report is the source.
| Acquired | Buyer | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|---|
| Alimera Sciences, Inc | ANI Pharmaceuticals, Inc. | 2024 | — | $419 M | — | Annual report |
Funding rounds
5 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2023 | $81 M | No. 5 | $50 to $250 million | equity, options | SEC | |
| Apr 2021 | $10 M | No. 4 | $10 to $50 million | equity | SEC | |
| Jan 2014 | $38 M | No. 3 | $10 to $50 million | equity | SEC | |
| Oct 2012 | $40 M | No. 2 | $10 to $50 million | equity, options | SEC | |
| Aug 2009 | $5 M | No. 1 | $2 to $10 million | equity, options | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Alimera Sciences Inc. had revenue between $25 million and $100 million when it filed its newest notice of a funding round (May 2023).
SEC Form D (revenue range) · May 2023
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · May 2023
Products and services#
No products or services of Alimera Sciences Inc. are on record.
Investors#
41 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Bavp, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Caligan Partners LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Calvin W. Roberts | Person | not stated | not stated | Held Series B and C preferred stock, director (Form 3, 2010) | SEC Form 3 |
| Deerfield Management Company, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt III, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Mgmt L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design Fund III, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design Fund II, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Private Design International II, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Deerfield Special Situations Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2015) | SEC Form 3 |
| Domain Partners VI, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| DP VI Associates, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Intersouth Affiliates V LP | Fund or asset manager | not stated | not stated | Held Series A, B and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Intersouth Associates VII, LLC | Other | not stated | not stated | Held Series C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Intersouth Associates VI, LLC | Other | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Intersouth Associates V, LLC | Other | not stated | not stated | Held Series A, B and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Intersouth Partners VII L.P. | Fund or asset manager | not stated | not stated | Held Series C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Intersouth Partners VI LP | Fund or asset manager | not stated | not stated | Held Series A, B and C preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Intersouth Partners V, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Palo Alto Healthcare Fund II L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Palo Alto Healthcare Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Palo Alto Healthcare Master Fund, L.P. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Palo Alto Investors | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Palo Alto Investors LP | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Polaris Venture Management Co IV LLC | Venture capital | not stated | not stated | Held Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Polaris Venture Partners Entrepreneurs Fund IV LP | Venture capital | not stated | not stated | Held Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Polaris Venture Partners IV LP | Venture capital | not stated | not stated | Held Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Scale Venture Management I, LLC | Venture capital | not stated | not stated | Held Series A, B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Sofinnova Management VIII, L.L.C. | Fund or asset manager | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| Sofinnova Venture Partners VIII, L.P. | Venture capital | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2012) | SEC Form 3 |
| VEF Management IV, LLC | Fund or asset manager | not stated | not stated | Held Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Velan Capital Holdings LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Velan Capital Investment Management LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Velan Capital Management LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Velan Capital Master Fund LP | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Velan Capital SPV I LLC | Fund or asset manager | not stated | not stated | Held Series B preferred stock, 10% owner (Form 3, 2023) | SEC Form 3 |
| Venrock Associates IV L.P. | Fund or asset manager | not stated | not stated | Held Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Venrock Entrepreneurs Fund IV L.P. | Fund or asset manager | not stated | not stated | Held Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Venrock Management IV, LLC | Fund or asset manager | not stated | not stated | Held Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Venrock Partners, L.P. | Fund or asset manager | not stated | not stated | Held Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
| Venrock Partners Management, LLC | Fund or asset manager | not stated | not stated | Held Series B, C and C-1 preferred stock, 10% owner (Form 3, 2010) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 5 rounds above had up to 25 investors.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| David S. Holland | Executive officer | May 2023 |
| Philip S. Ashman | Executive officer | May 2023 |
| Richard S. Eiswirth, Jr. | Executive officer | May 2023 |
| Russell S. Skibsted | Executive officer | May 2023 |
| David Philip Holland | Chief Marketing Officer, Senior Vice President Corporate Communication and Managed Markets | Apr 2021 |
| J. Philip Jones | Chief Financial Officer | Apr 2021 |
| Philip Philip Ashman | Chief Operating Officer and Senior Vice President Commercial Operations Europe | Apr 2021 |
| Richard S. Eiswirth | President, Chief Executive Officer and Director | Apr 2021 |
| C. Daniel Myers | Executive officer | Feb 2014 |
| Charles Daniel Myers | Executive officer | Sep 2009 |
| David Holland | Executive officer | Sep 2009 |
| Kenneth Green | Executive officer | Sep 2009 |
| Richard Eiswirth | Executive officer | Sep 2009 |
| Susan Caballa | Executive officer | Sep 2009 |
| Adam S. Morgan | Director | May 2023 |
| Daniel S. Myers | Director | May 2023 |
| Erin S. Parsons | Director | May 2023 |
| Garheng S. Kong | Director | May 2023 |
| John J. Snisarenko | Director | May 2023 |
| Michael S. Kaseta | Director | May 2023 |
| Peter J. Pizzo III | Director | May 2023 |
| Richard S. Eiswirth, Jr. | Director | May 2023 |
| Daniel R. Myers | Director | Apr 2023 |
| Erin R. Parsons | Director | Apr 2023 |
| James R. Largent | Director | Apr 2023 |
| Roger J. Sawheny | Director | Apr 2023 |
| Brian K. Halak | Director | Apr 2021 |
| C. Daniel Myers | Director | Apr 2021 |
| Garheng K. Kong | Director | Apr 2021 |
| Mary T. Szela | Director | Apr 2021 |
| Peter J. Pizzo | Director | Apr 2021 |
| Richard S. Eiswirth | President, Chief Executive Officer and Director | Apr 2021 |
| Brian S. Halak | Director | Feb 2014 |
| Calvin J. Roberts | Director | Feb 2014 |
| Glen S. Bradley | Director | Feb 2014 |
| Mark S. Brooks | Director | Feb 2014 |
| Phil J. Tracy | Director | Feb 2014 |
| Calvin W. Roberts | Director | Oct 2012 |
| Phil W. Tracy | Director | Oct 2012 |
| Anders Hove | Director | Sep 2009 |
About
American biopharmaceutical sales company.
Acquired (Jan 1, 2024). Acquired by ANI Pharmaceuticals, Inc..